Legal Representation
Attorney
Aaron D. Hendelman
USPTO Deadlines
Next Deadline
1921 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-05)
Due Date
November 05, 2030
Grace Period Ends
May 05, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
27 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 5, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 5, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 1, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 1, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 1, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 1, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jul 31, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Jul 31, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| May 14, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 3, 2024 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED | Loading... |
| Apr 1, 2024 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Feb 29, 2024 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Feb 23, 2024 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Sep 20, 2023 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Aug 22, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 22, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 2, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 17, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 14, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 10, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 10, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 10, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 28, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 5, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 22, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and related diseases and disorders, none of the aforementioned offerings being in the nature of dietetic substances for medical use, foods for special medical purposes, or special nutritional food products for medical purposes.
First Use Anywhere:
20230300
First Use in Commerce:
20230300
Class 042
providing medical and scientific research information in the fields of
pharmaceuticals and biotechnology
First Use Anywhere:
20230300
First Use in Commerce:
20230300
Additional Information
Pseudo Mark
EXPLORE FORTY FOUR; EXPLORE FOUR FOUR
Classification
International Classes
005
042